Transforming Discovery & Translational Fibrosis Research into Disease Modifying IPF Therapeutics
The inaugural Idiopathic Pulmonary Fibrosis (IPF) Summit is the only event to focus solely on IPF.
This unique meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.
Across 3 jam-packed days the brightest minds from the likes of Boehringer Ingelheim, Promedior, Fibrogen and many more will be sharing their insight and lessons learned to collectively enable the community to:
Join your peers in Boston to overcome the challenges that are preventing you from accelerating the development of your IPF candidate.
"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee